biotech · Fabry Disease (X-linked lysosomal storage disease). · Kidney Transplant Rejection · SGMO
SANGAMO THERAPEUTICS
SANGAMO THERAPEUTICS, INC
Sangamo Therapeutics is a biotech organization headquartered in Brisbane, USA. It trades on NYSE under ticker SGMO. Primary therapeutic focus areas include Fabry Disease (X-linked lysosomal storage disease)., Kidney Tran
7000 Marina Blvd, Brisbane, California 94005, US HQ
1995 Founded
266 Employees
Public company Type
SGMO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 7000 Marina Blvd, Brisbane, California 94005, US
- Founded
- 1995
- Employees
- 266
- Programs
- 25
- Drugs
- 14
- Patents
- 192
TX200-TR101
Phase 3 · small molecule · Kidney Transplant Rejection
TX200-TR101 for Kidney Transplant Rejection is a Phase 3 program (small_molecule) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).
Internal code TX200-KT03
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- SANGAMO THERAPEUTICS, INC
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Kidney Transplant Rejection
- Status
- active
- Trials
- 1